Acute Administration of Pioglitazone Attenuates Morphine Withdrawal Syndrome in Rat: A Novel Role of Pioglitazone

Abstract

Background:

Long-term exposure to opiates such is morphine induces dependence.

Purpose:

The purpose of the present study was to investigate the effects of the acute administration of pioglitazone, a selective agonist of peroxisome proliferator activated receptors gamma (PPAR-γ), on the morphine withdrawal syndrome in the rat.

Methods:

Male Wistar rats (200–250 g) were selected randomly and divided into 8 groups including 2 non-dependent groups and 6 morphine-dependent groups which were received additive doses of morphine subcutaneously at an interval of 12 h for 9 continuous days. On the ninth day, only the morning dose of morphine was injected and 2 h later, morphine withdrawal was precipitated by naloxone and then ten distinct withdrawal behaviors were recorded for 45 min. Pioglitazone (5, 10, 20 and 40 mg/kg) was gavaged 2 h before naloxone injection. It is worth noting that 1 h before the pioglitazone (40 mg/kg) gavage, GW-9662 (2 mg/kg), a selective PPAR-γ antagonist, was administrated in order to evaluate the possible role of the PPAR-γ.

Result and Discussion:

The results of this study showed that administration of pioglitazone (40 mg/kg) decreased all withdrawal signs and the statistical analysis indicated that pioglitazone could attenuate the total withdrawal scores significantly. Administration of GW-9662 had no significant effect on pioglitazone attenuation effect on morphine withdrawal symptoms.

Conclusion:

Taking together, it was concluded that acute oral administration of pioglitazone prevented naloxone-precipitated withdrawal symptoms and GW-9662 could not revert its effect on morphine withdrawal syndrome. It seems that pioglitazone suppresses morphine withdrawal syndrome through PPAR-γ independent mechanisms.

Key words

pioglitazone - GW-9662 - morphine withdrawal - naloxone - rat

• References

• 1 Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation – an update. Toxicol Pathol 2001; 29: 224-231
• 2 Kumar P, Kaundal RK, More S et al. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson’s disease. Behav Brain Res 2009; 197: 398-403
• 3 Martin HL, Mounsey RB, Mustafa S et al. Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPARgamma) reveals a role for anti-oxidant protection in a model of Parkinson’s disease. Exp Neurol 2012; 235: 528-538
• 4 Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748-759
• 5 Shibata N, Kawaguchi-Niida M, Yamamoto T et al. Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology 2008; 28: 387-398
• 6 Semple BD, Noble-Haeusslein LJ. Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors. Exp Neurol 2011; 229: 195-197
• 7 Pancani T, Phelps JT, Searcy JL et al. Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem 2009; 109: 1800-1811
• 8 Toriumi Y, Hiraoka M, Watanabe M et al. Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase. FEBS Lett 2003; 553: 222-419
• 9 Gardner OS, Shiau CW, Chen CS et al. Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. J Biol Chem 2005; 280: 10109-10118
• 10 Hutchinson MR, Coats BD, Lewis SS et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008; 22: 1178-1189
• 11 Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251: 85-87
• 12 Charkhpour M, Jafari RM, Ghavimi H et al. Duloxetine Attenuated Morphine Withdrawal Syndrome in the Rat. Drug Res 2013; 21: 21
• 13 Moradi S, Charkhpour M, Ghavimi H et al. Gap junction blockers: a potential approach to attenuate morphine withdrawal symptoms. J Biomed Sci 2013; 20: 77
• 14 Riahi E, Mirzaii-Dizgah I, Karimian SM et al. Attenuation of morphine withdrawal signs by a GABAB receptor agonist in the locus coeruleus of rats. Behav Brain Res 2009; 196: 11-14
• 15 Inestrosa NC, Godoy JA, Quintanilla RA et al. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 2005; 304: 91-104
• 16 Jia HB, Wang XM, Qiu LL et al. Spinal neuroimmune activation inhibited by repeated administration of pioglitazone in rats after L5 spinal nerve transection. Neurosci Lett 2013; 543: 130-135
• 17 Nicolakakis N, Aboulkassim T, Ongali B et al. Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 2008; 28: 9287-9296
• 18 Ji H, Wang H, Zhang F et al. PPARgamma agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Inflamm Res 2010; 59: 921-929
• 19 Feinstein DL, Spagnolo A, Akar C et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem Pharmacol 2005; 70: 177-188
• 20 Javadi S, Ejtemaeimehr S, Keyvanfar HR et al. Pioglitazone potentiates development of morphine-dependence in mice: possible role of NO/cGMP pathway. Brain Res 2013; 13: 22-37
• 21 Salehi-Sadaghiani M, Javadi-Paydar M, Gharedaghi MH et al. NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacology 2012; 223: 345-355
• 22 Allahtavakoli M, Shabanzadeh A, Roohbakhsh A et al. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol 2007; 101: 309-314
• 23 Watkins LR, Hutchinson MR, Johnston IN et al. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 2005; 28: 661-669